Best-In-Class VALUE BASED CARE Programs for People with KIDNEY DISEASE
Fresenius Health Partners is the leader in renal value based care. Our value based care programs allow for partnerships with payors and the government to reduce the overall cost of care while helping people with kidney disease reach their health goals. We support the entire spectrum of renal care, from chronic kidney disease (CKD) to end stage renal disease (ESRD), including kidney transplantation, supportive care, and all modalities of dialysis. With unparalleled industry expertise, we leverage artificial intelligence, advanced analytics, technological capabilities, and platforms to support early interventions. We are uniquely equipped to help your organization, and the patients you serve, succeed.
WHAT SETS US APART
Being part of the largest vertically integrated renal company, we're able to leverage the partnerships, relationships, and vast knowledge of our physician partners and their practices. We work directly with InterWell Health, the country's largest network of independent, high-performing nephrologists, as well as a network of nephrology partners in Kidney Contracting Entities (KCEs) participating in the CMS Kidney Care Choices (KCC) Model. When you partner with our fully aligned nephrology network that is committed to delivering physician-led value based care to members — together we can optimize our impact on the health outcomes of renal patients.
Proven Predictive Modeling
Our programs are powered by leading technology and utilize proprietary algorithms and predictive models to identify opportunities for impactful interventions and supportive care. We’re able to provide patient assistance right when it’s needed, to enhance care and outcomes.
Extensive Renal Expertise
We're the worldwide leaders in renal care, with direct access to top physicians, clinicians, scientists, analysts, and researchers. We leverage early education, timely care interventions, the support of nephrologists, and Fresenius Kidney Care’s Transitional Care Units to help successfully transition a high percentage of new and in-center dialysis patients to home dialysis — as well as help increase access to kidney transplants and success with home dialysis.
PROGRAMS FOR PAYORS
Our KidneyCare:365 Health Programs support payors’ efforts to reduce the overall cost of care for those living with chronic kidney disease (CKD) and end stage renal disease (ESRD).
PROGRAMS FOR NEPHROLOGISTS
Our KidneyCare:365 Care Choices Program supports a large patient population by pairing our experience as the largest vertically integrated renal care company with nephrologists across the country.
A REPUTATION FOR SUCCESS
Since 2005, we’ve built an outstanding track record in empowering better patient outcomes. We maintain long-standing, trusted relationships with payors — and we are the largest participant in government value based care programs for kidney disease. Today, our services and support are expanding to meet the unique needs of patients with CKD and ESRD.
Medical expenses currently managed in a risk arrangement
Value based care program participants over the past eight years
Reduction in inpatient
from 1.72to 1.28 per member
Increase in our TQS
(total quality score)5
Increase in home therapy
partnership that delivers results
Together we can enhance the quality of integrated kidney care for people with kidney disease. Our programs have an unprecedented level of alignment among key stakeholders responsible for providing and paying for renal care services for members. Coupled with the high-quality attention physicians already provide, our timely interventions and hands-on services and support help keep patients out of the hospital and lower the cost of care.
insights for you
1. Based on current VBC partnerships and CMS KCC models
2. Intervention and control groups data include patients with First Day of Dialysis between 4/1/17-12/31/19
3. Results substantiated on internal market research of member population from 2019 to 2021
4. Results substantiated on internal market research of member population from 2013 to 2021
5. Results substantiated on internal market research of member population of over 40,000 from 2016 to 2020